SCHEMBL1110190

SCHEMBL1110190

COc1cc(NS(=O)(=O)c2cc(Cl)cc(Cl)c2)c2ncccc2c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC40A1 Q9NP59 13/20 0.77
MEN1 O00255 5/20 0.77
KMT2A Q03164 5/20 0.77
TDP1 Q9NUW8 5/20 0.77
CXCR2 P25025 2/20 0.73
POLB P06746 1/20 0.73
LMNA P02545 1/20 0.73
TP53 P04637 1/20 0.73
MAPT P10636 1/20 0.73
HPGD P15428 1/20 0.73
TSHR P16473 1/20 0.73
AGTR1 P30556 1/20 0.73
SMN1; SMN2 Q16637 1/20 0.73
NPSR1 Q6W5P4 1/20 0.73
CKS1B P61024 1/20 0.64
SKP2 Q13309 1/20 0.64
NFKBIA P25963 1/20 0.61
RELA Q04206 1/20 0.61
GLO1 Q04760 2/20 0.60
CXCR4 P61073 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13633886 0.87 MEN1 (1.00) SLC40A1MEN1KMT2ATDP1CXCR2
SCHEMBL7197593 0.87 SLC40A1 (1.00) SLC40A1MEN1KMT2ATDP1CXCR2
SCHEMBL1505430 0.85 KMT2A (1.00) SLC40A1MEN1KMT2ATDP1CXCR2
SCHEMBL22076984 0.85 MEN1 (1.00) SLC40A1MEN1KMT2ATDP1CXCR2
SCHEMBL29575795 0.85 KMT2A (1.00) SLC40A1MEN1KMT2ATDP1CXCR2
SCHEMBL4489851 0.84 MEN1 (0.84) SLC40A1MEN1KMT2ATDP1CXCR2
SCHEMBL22111633 0.84 MEN1 (0.84) SLC40A1MEN1KMT2ATDP1CXCR2
SCHEMBL11995649 0.84 SLC40A1 (1.00) SLC40A1MEN1KMT2ATDP1CXCR2
SCHEMBL4484159 0.84 SLC40A1 (0.71) SLC40A1MEN1KMT2ATDP1CXCR2
SCHEMBL11973509 0.83 SLC40A1 (1.00) SLC40A1MEN1KMT2ATDP1CXCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-03 US disclosed
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-03 US disclosed
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-03 US disclosed
EP-2279173-A1 NEW ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-02-02 EP disclosed
WO-2009127723-A1 NEW ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-10-22 WO disclosed
WO-2009127723-A1 NEW ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS SULT2A1, UGT1A1, SLC5A1 SLC40A1 2186/4885MEN1 3970/4885KMT2A 645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.